Hematopoietic Stem and Progenitor Biology
Program: Oral and Poster Abstracts
Session: 501. Hematopoietic Stem and Progenitor Biology: Poster I
Program: Oral and Poster Abstracts
Session: 501. Hematopoietic Stem and Progenitor Biology: Poster I
Saturday, December 5, 2015, 5:30 PM-7:30 PM
Hall A, Level 2
(Orange County Convention Center)
Rare endothelial cells in the aorta-gonad-mesonephros (AGM) transition into hematopoietic stem cells (HSCs) during embryonic development. Lineage tracing experiments indicate that HSCs emerge from Cadherin 5 (Cdh5, VE-cadherin)+ endothelial precursors, and isolated populations of Cdh5+ cells from mouse embryos and embryonic stem (ES) cells can be differentiated into hematopoietic cells. Cdh5 has also been widely implicated as a marker of AGM-derived hemogenic endothelial cells. Since Cdh5-/- mice embryos die before the first HSCs emerge, it is unknown if Cdh5 has a direct role in HSC emergence. Our previous genetic screen yielded malbec (mlbbw306), a zebrafish mutant for cdh5, with normal embryonic and definitive blood. Utilizing time-lapse imaging, parabiotic surgical pairing of zebrafish embryos, and blastula transplantation assays, we show that HSCs emerge, migrate, engraft, and differentiate in the absence of cdh5 expression. By tracing Cdh5-/-GFP+/+ cells in chimeric mice, we demonstrated that Cdh5-/- GFP+/+ HSCs emerging from E10.5 and E11.5 AGM or derived from E13.5 fetal liver not only differentiate into hematopoietic colonies but also engraft and reconstitute multi-lineage adult blood. These data establish that Cdh5, a marker of hemogenic endothelium in the AGM, is dispensable for the transition of hemogenic endothelium to HSCs.
Disclosures: Bauer: Biogen: Research Funding ; Editas Medicine: Consultancy . Zon: FATE Therapeutics: Employment , Equity Ownership , Membership on an entity’s Board of Directors or advisory committees , Other: Founder ; Scholar Rock: Employment , Equity Ownership , Membership on an entity’s Board of Directors or advisory committees , Other: Founder . Orkin: Editas Medicine: Membership on an entity’s Board of Directors or advisory committees ; Biogen: Research Funding ; Pfizer: Research Funding ; Sangamo Biosciences: Consultancy .
See more of: 501. Hematopoietic Stem and Progenitor Biology: Poster I
See more of: Hematopoietic Stem and Progenitor Biology
See more of: Oral and Poster Abstracts
See more of: Hematopoietic Stem and Progenitor Biology
See more of: Oral and Poster Abstracts
*signifies non-member of ASH